Common name
but-1-ene
IUPAC name
but-1-ene
SMILES
C(C)C=C
Common name
but-1-ene
IUPAC name
but-1-ene
SMILES
C(C)C=C
INCHI
InChI=1S/C4H8/c1-3-4-2/h3H,1,4H2,2H3
FORMULA
C4H8
Common name
but-1-ene
IUPAC name
but-1-ene
Molecular weight
56.106
clogP
0.885
clogS
-0.930
Frequency
0.0100
HBond Acceptor
0
HBond Donor
0
Total PolarSurface Area
0
Number of Rings
0
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00763 | Tiagabine |
|
Anticonvulsants; Neurotransmitter Uptake Inhibitors; GABA Agonists; Nervous System; Antiepileptics; Fatty Acid Derivatives; CYP3A4 Inhibitors; | For the treatment of partial seizures. |
| FDBD00767 | Paricalcitol |
|
Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Anti-Parathyroid Agents; Calcium Homeostasis; CYP3A4 Inhibitors; | For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4. |
| FDBD00774 | Dinoprostone |
|
For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical ; | |
| FDBD00887 | Cerulenin |
|
Antifungal Agents; Fatty Acid Synthesis Inhibitors; | For use as a biochemical tool, Cerulenin is shown to cause dramatic weight loss in animals. |
| FDBD00921 | Dihydrotachysterol |
|
Bone Density Conservation Agents; Vitamins; Antithyroid Agents; Vitamin D; Antihypocalcemic Agents; Alimentary Tract and Metabolism; Vitamin D and Analogues; | Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis). |
| FDBD01007 | Dinoprost Tromethamine |
|
Oxytocics; Abortifacient Agents, Nonsteroidal; Angiography; Stimulants, Uterine; Tromethamine; | Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography. |
| FDBD01284 | Calcipotriol |
|
Dermatologic Agents; Dermatologicals; Antipsoriatics for Topical Use; Antipsoriatics; Drugs for Keratoseborrheic Disorders, Topical Use (Atc Human: Antipsoriatics for Topical Use); Drugs for Keratoseborrheic Disorders (Atc Human: Antipsoriatics); | For the treatment of moderate plaque psoriasis in adults. |
| FDBD01305 | Oleic Acid |
|
; | |
| FDBD01412 | Doxercalciferol |
|
Bone Density Conservation Agents; Vitamins; Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins; Anti-Parathyroid Agents; Calcium Homeostasis; | Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. |
| FDBD01431 | Ethanolamine Oleate |
|
Sclerosing Solutions; Cardiovascular System; Vasoprotectives; Sclerosing Agents for Local Injection; Antivaricose Therapy; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); | For the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. |
29 ,
3
